These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22952347)

  • 61. DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.
    Minuzzo S; Agnusdei V; Pusceddu I; Pinazza M; Moserle L; Masiero M; Rossi E; Crescenzi M; Hoey T; Ponzoni M; Amadori A; Indraccolo S
    Carcinogenesis; 2015 Jan; 36(1):115-21. PubMed ID: 25355291
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.
    Ridgway J; Zhang G; Wu Y; Stawicki S; Liang WC; Chanthery Y; Kowalski J; Watts RJ; Callahan C; Kasman I; Singh M; Chien M; Tan C; Hongo JA; de Sauvage F; Plowman G; Yan M
    Nature; 2006 Dec; 444(7122):1083-7. PubMed ID: 17183323
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis.
    Funahashi Y; Hernandez SL; Das I; Ahn A; Huang J; Vorontchikhina M; Sharma A; Kanamaru E; Borisenko V; Desilva DM; Suzuki A; Wang X; Shawber CJ; Kandel JJ; Yamashiro DJ; Kitajewski J
    Cancer Res; 2008 Jun; 68(12):4727-35. PubMed ID: 18559519
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
    Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
    Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
    Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Bone marrow-derived endothelial progenitors expressing Delta-like 4 (Dll4) regulate tumor angiogenesis.
    Real C; Remédio L; Caiado F; Igreja C; Borges C; Trindade A; Pinto-do-Ó P; Yagita H; Duarte A; Dias S
    PLoS One; 2011 Apr; 6(4):e18323. PubMed ID: 21483741
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Notch signaling regulates tumor angiogenesis by diverse mechanisms.
    Dufraine J; Funahashi Y; Kitajewski J
    Oncogene; 2008 Sep; 27(38):5132-7. PubMed ID: 18758482
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dll4-Notch signaling in regulation of tumor angiogenesis.
    Liu Z; Fan F; Wang A; Zheng S; Lu Y
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):525-36. PubMed ID: 24114288
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Notch ligand delta-like 4 blockade attenuates atherosclerosis and metabolic disorders.
    Fukuda D; Aikawa E; Swirski FK; Novobrantseva TI; Kotelianski V; Gorgun CZ; Chudnovskiy A; Yamazaki H; Croce K; Weissleder R; Aster JC; Hotamisligil GS; Yagita H; Aikawa M
    Proc Natl Acad Sci U S A; 2012 Jul; 109(27):E1868-77. PubMed ID: 22699504
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Control of endothelial cell tube formation by Notch ligand intracellular domain interactions with activator protein 1 (AP-1).
    Forghany Z; Robertson F; Lundby A; Olsen JV; Baker DA
    J Biol Chem; 2018 Jan; 293(4):1229-1242. PubMed ID: 29196606
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth.
    Jia X; Wang W; Xu Z; Wang S; Wang T; Wang M; Wu M
    Sci Rep; 2016 Jun; 6():27985. PubMed ID: 27301650
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Regulation of CXCR4 by the Notch ligand delta-like 4 in endothelial cells.
    Williams CK; Segarra M; Sierra Mde L; Sainson RC; Tosato G; Harris AL
    Cancer Res; 2008 Mar; 68(6):1889-95. PubMed ID: 18339870
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of Dll4/notch and HIF-1a -VEGF signaling in the angiogenesis of missed abortion.
    Fang Y; Yu S; Ma Y; Sun P; Ma D; Ji C; Kong B
    PLoS One; 2013; 8(8):e70667. PubMed ID: 23950980
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications.
    Li JL; Harris AL
    Front Biosci (Landmark Ed); 2009 Jan; 14(8):3094-110. PubMed ID: 19273260
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
    Baker CH; Solorzano CC; Fidler IJ
    Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Metastasis is impaired by endothelial-specific Dll4 loss-of-function through inhibition of epithelial-to-mesenchymal transition and reduction of cancer stem cells and circulating tumor cells.
    Mendonça L; Trindade A; Carvalho C; Correia J; Badenes M; Gigante J; Duarte A
    Clin Exp Metastasis; 2019 Aug; 36(4):365-380. PubMed ID: 31119445
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The protein tyrosine phosphatase PTPRJ/DEP-1 contributes to the regulation of the Notch-signaling pathway and sprouting angiogenesis.
    Fournier P; Viallard C; Dejda A; Sapieha P; Larrivée B; Royal I
    Angiogenesis; 2020 May; 23(2):145-157. PubMed ID: 31598898
    [TBL] [Abstract][Full Text] [Related]  

  • 80. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo.
    Jenkins DW; Ross S; Veldman-Jones M; Foltz IN; Clavette BC; Manchulenko K; Eberlein C; Kendrew J; Petteruti P; Cho S; Damschroder M; Peng L; Baker D; Smith NR; Weir HM; Blakey DC; Bedian V; Barry ST
    Mol Cancer Ther; 2012 Aug; 11(8):1650-60. PubMed ID: 22679110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.